The Pan Cancer Panel is a robust and comprehensive NGS assay, rigorously engineered to measure biomarkers like Tumor Mutational Burden (TMB), Microsatellite Instability (MSI) with quality performance even with limited and complex sample inputs like FFPE samples. These markers play a pivotal role in cancer immunotherapy, guiding treatment decisions towards personalized and effective care. The panel is based on Hybridisation Enrichment workflow. It can detect mutations like SNV, INDELS, CNV, Chromosomal Rearrangement, fusions & splice variants.

The panel is also adept in detecting variants of viruses such as Epstein-Barr virus (EBV) and Human Papillomaviruses (HPV), that are also known to be associated with onset and progression of different cancers in humans. We understand that cancer is complex, and that's why we encompass these elements to provide a holistic view of the genomic landscape, facilitating deeper insights into cancer biology and paving the way for more targeted and effective therapies.

This panel uses unique molecular indices for the screening of a family of 524 genes which comprise of 681 gene subtypes using as little as 50 ng genomic DNA. The panel covers major cancers including cancers of breast, lung, stomach, thyroid, leukemia, pancreatic, colon etc.

The panel is supported with G2M’s proprietary data analysis platform “Cliseq Interpreter”, a cloud based data analytics and tertiary reporting software for analyzing the complex NGS data output from the sequencer machine.